Press Releases

IFF today announced the opening of its new Nourish Innovation Lab at the company’s Union Beach, New Jersey research and development center. In the state-of-the-art lab, scientists—including flavorists and food designers—will leverage tools, technologies and ingredient expertise to offer customers full product design, driving growth in the global food and beverage markets by fast forwarding innovation. “This new facility is a testament to how we pioneer innova

Jemincare, a leading Chinese pharmaceutical company , announced today that it and its wholly-owned subsidiary Shanghai Jemincare Pharmaceutical Co., Ltd. have entered into an exclusive worldwide license agreement with Roche (SIX: RO, ROG;OTCQX: RHHBY ) and Genentech, a member of the Roche Group, for the development and commercialization of their androgen receptor degrader JMKX002992. Under the terms of the agreement, Genentech will receive an exclusive license to develop and commerc

Zealand Pharma A/S, a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 3,874 divided into 3,874 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each

ABVC BioPharma, Inc.  a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that, on August 2, 2022, approval was received from the Ethics Committee (EC) of the Ramathibodi Hospital, Mahidol University to conduct the Vitargus Phase II Study Protocol (ABV-1701-02). This follows a similar approval received on July 18, 2022, by Srinagarind Hospital, Khon Kaen University of Thailand. Both hospital

Eagle Pharmaceuticals, Inc. today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware’s decision that Eagle’s vasopressin product does not infringe on any of the patents asserted by Par Pharmaceutical, Inc. (“Par”). Par previously sued Eagle in 2018, alleging infringement of several of its patents and a trial was held in July 2021. The District Court held that Eagle did not infringe on

QPharma, the leading provider of cloud-based compliance solutions, today launched the next version of Ti OrderPoint®, a next-generation direct-to-rep (DTR) solution. The new release of OrderPoint now includes a re-designed user interface, additional compliance features, and reports and dashboards to address greater needs for insights and intelligence. While Pharma companies have long invested in CRMs to help sales reps manage the relationships with their health care practitioner

 Emery Pharma has officially expanded its state-of-the-art laboratories which feature a brand-new High-Resolution Orbitrap Mass Spectrometer, enabling Emery Pharma to expand its service offerings. The extension of its new laboratory is streamlined to support the research and development of large molecule drugs including, biologics, antibody-drug conjugates, biosimilars and more.  Emery Pharma's expertise continues to grow with the addition of Dr. Rodney Bannwart. Dr. B

Evoke Pharma, Inc.  a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, an independent provider of global commercial services to the life science industry, today announced that Evoke, through its wide-scale commercialization partnership with EVERSANA, is launching a telehealth solution for patients. The new Direct-to-Patient Technology Solution will leverage EVERSANA’s partnership with UpScriptHealth,

 Tris Pharma, Inc. (Tris) a fully integrated pharmaceutical company with a robust portfolio of CNS products announced today that DYANAVEL® XR (amphetamine) extended-release tablets, for oral use, CII are now available in pharmacies. DYANAVEL XR was approved by the U.S. Food and Drug Administration for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older. In a double-blind, placebo-controlled, fixed-dose Phase 3 study in adults with

Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today the expansion of its partnership with Albireo to a multi-regional agreement to commercialize Odevixibat in Canada and Israel,  for the treatment of patients with cholestatic liver diseases. "Albireo's vote of confidence in the commercial solution Medison offers allows us to continue demonstrating